Last mentioned: Mar 25, 2026
Charles Schwab reported record-breaking 2025 results with $12 trillion in client assets and a 50% surge in adjusted EPS, signaling a powerful recovery in the brokerage sector. Conversely, life sciences firm MaxCyte is navigating a 15% revenue decline as cell therapy customers consolidate programs and reduce capital expenditures.
This page surfaces every story mentioning Douglas J. Swirsky across our finance coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running finance beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Douglas J. Swirsky was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |